title: [Antibiotic therapy of febrile neutropenic patients: prospective study at a hematologic department].
abstract: OBJECTIVE
  Many antibiotics have been studied in clinical trials in neutropenic patients with fever. Few have been evaluated in the everyday clinical setting. The aim of our study was to analyze the antibiotic strategy used in an adult hematology unit after guidelines had been set up.
  
  
  METHODS
  A prospective study was conducted by a pharmacy team not directly working with the prescribing unit. Parameters recorded were drug use, treatment duration and reasons for changing successive drugs. Bacterial ecology data were analyzed.
  
  
  RESULTS
  Seventy-four patients were included in the study. Mean treatment duration was 14.8 days and was related to degree of neutropenia: 10 days in case of short neutropenia and 16.2 days for prolonged neutropenia. The most frequent first intention prescription was for non-anti-pseudomonas fl-lactams plus tobramycin, modifications made were: substitution with an anti-pseudomonas fl-lactam and introduction of a glycopeptide as second or third intention drugs. Imipenem and fluoroquinolones were used little. Mean duration of each regimen was 4 days. Initial treatment was generally empirical (7% of the prescriptions were based on documented susceptibility data). The highest rate of bacteriological data (20%) was obtained during the first intention regiment (42% coagulase-negative staphylococci, 14% Pseudomonas aeruginosa). The main reason for changing antibiotics was persistent or renewed fever. No bacterial caused deaths were recorded. No multiresistant Gram negative bacilli were selected.
  
  
  CONCLUSIONS
  Reasonable use of antibiotics is possible in neutropenic patients with fever. First intention anti-pseudomonas fl-lactams and glycopeptides are not indispensable in most of these patients. An analysis of practice in the everyday clinical setting is required for optimal use of antibiotics.
authors.affiliation: Service d'Hématologie, CHU de Besançon.
authors.forename: S
authors.initials: S
authors.lastname: Limat
authors.forename: C
authors.initials: C
authors.lastname: Cornette
authors.forename: E
authors.initials: E
authors.lastname: Deconinck
authors.forename: M C
authors.initials: MC
authors.lastname: Woronoff-Lemsi
authors.forename: J Y
authors.initials: JY
authors.lastname: Cahn
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005334:Fever / Q000188:drug therapy; D006020:Glycopeptides / Q000627:therapeutic use; D006405:Hematology; D006748:Hospital Departments; D006801:Humans; D007769:Lactams; D009503:Neutropenia / Q000188:drug therapy* / Q000382:microbiology; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D007769:Lactams